La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Protagenic Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Protagenic Therapeutics..

Protagenic Therapeutics (NASDAQ:PTIX) Azioni, Catena delle Opzioni

Protagenic Therapeutics

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics Inc

Legal

Press Releases

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

Contracts

Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders

PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TXNM, SVT, INZY, PTIX on Behalf of Shareholders

Offerings

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, TXNM, SVT, PTIX on Behalf of Shareholders

News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders

Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance

INZY

PTIX

TXNM

VIGL

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AIM ImmunoTech

Aptevo Therapeutics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

enGene Holdings

Ensysce Biosciences

Entero Therapeutics

Galecto

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

Mainz Biomed

Oragenics

Onconetix

Polyrizon

PharmaCyte Biotech

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Sunshine Biopharma

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

SILO Pharma

Spruce Biosciences

Alaunos Therapeutics, Inc. - Common Stock

Comments

Protagenic Therapeutics

Protagenic Therapeutics (PTIX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO